ECSP15013227A - Formulaciones acuosas estables de adalimumab - Google Patents

Formulaciones acuosas estables de adalimumab

Info

Publication number
ECSP15013227A
ECSP15013227A ECIEPI201513227A ECPI201513227A ECSP15013227A EC SP15013227 A ECSP15013227 A EC SP15013227A EC IEPI201513227 A ECIEPI201513227 A EC IEPI201513227A EC PI201513227 A ECPI201513227 A EC PI201513227A EC SP15013227 A ECSP15013227 A EC SP15013227A
Authority
EC
Ecuador
Prior art keywords
adalimumab
stable aqueous
aqueous formulations
methods
compositions
Prior art date
Application number
ECIEPI201513227A
Other languages
English (en)
Inventor
Robert W Payne
Mark Manning
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237778&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP15013227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of ECSP15013227A publication Critical patent/ECSP15013227A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)

Abstract

Composiciones farmacéuticas acuosas de adalimumab adecuadas para un almacenamiento a largo plazo de adalimumab, métodos de elaboración de estas composiciones, métodos de administración y conjuntos de elementos que las contienen.
ECIEPI201513227A 2012-09-07 2015-04-06 Formulaciones acuosas estables de adalimumab ECSP15013227A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698138P 2012-09-07 2012-09-07
US201361769581P 2013-02-26 2013-02-26
US201361770421P 2013-02-28 2013-02-28

Publications (1)

Publication Number Publication Date
ECSP15013227A true ECSP15013227A (es) 2016-01-29

Family

ID=50237778

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201513227A ECSP15013227A (es) 2012-09-07 2015-04-06 Formulaciones acuosas estables de adalimumab

Country Status (31)

Country Link
US (39) US20140186361A1 (es)
EP (2) EP3701968A1 (es)
JP (3) JP6463268B2 (es)
KR (3) KR102238677B1 (es)
CN (1) CN104768576A (es)
AR (1) AR092470A1 (es)
AU (3) AU2013312300A1 (es)
BR (1) BR112015004984A2 (es)
CA (2) CA3153799A1 (es)
CL (1) CL2015000574A1 (es)
CY (1) CY1123407T1 (es)
DK (1) DK2892550T3 (es)
DO (1) DOP2015000051A (es)
EA (2) EA201791717A1 (es)
EC (1) ECSP15013227A (es)
ES (1) ES2784861T3 (es)
HK (1) HK1210601A1 (es)
HR (1) HRP20200434T1 (es)
HU (1) HUE049282T2 (es)
IL (2) IL237583B (es)
LT (1) LT2892550T (es)
MX (1) MX2015003007A (es)
PE (2) PE20191815A1 (es)
PL (1) PL2892550T3 (es)
PT (1) PT2892550T (es)
RS (1) RS60226B1 (es)
SG (2) SG11201501715QA (es)
SI (1) SI2892550T1 (es)
TW (2) TWI698253B (es)
UY (1) UY35351A (es)
WO (1) WO2014039903A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
AU2013255413C1 (en) 2012-03-07 2016-03-24 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
TWI698253B (zh) 2012-09-07 2020-07-11 美商柯赫勒斯生物科學有限公司 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物
BR112015017619A2 (pt) * 2013-01-24 2017-11-21 Glaxosmithkline Ip Dev Ltd formulação líquida, uso de uma formulação, e, kit
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
IN2014MU01248A (es) * 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
ES2600488T3 (es) * 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP3156071A4 (en) * 2014-06-10 2018-01-10 Meiji Seika Pharma Co., Ltd. Stable aqueous adalimumab preparation
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2016120413A1 (en) * 2015-01-28 2016-08-04 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
BR112017016636A2 (pt) * 2015-02-13 2018-04-03 Sanofi Sa formulação líquida estável para anticorpos monoclonais
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017122121A1 (en) * 2016-01-12 2017-07-20 Dr. Reddy's Laboratories Limited Stable pharmaceutical composition
CA3013336A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
JP2019510078A (ja) * 2016-02-23 2019-04-11 セセン バイオ， インコーポレイテッド Ｉｌ−６アンタゴニスト製剤およびその使用
US20190060241A1 (en) * 2016-04-13 2019-02-28 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US20180043020A1 (en) * 2016-04-20 2018-02-15 Coherus Biosciences, Inc. Method of reducing immunogenicity of drug products
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
MX2018015960A (es) 2016-06-30 2019-03-21 Celltrion Inc Formulacion farmaceutica liquida estable.
EP3533441A4 (en) * 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
RU2756619C2 (ru) * 2017-03-16 2021-10-04 ЭлДжи КЕМ, ЛТД. Жидкая композиция антитела против TNF альфа
WO2018184693A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
CN111491664A (zh) * 2017-09-20 2020-08-04 阿尔沃科技Hf公司 阿达木单抗的药物制剂
EP3909607A4 (en) * 2019-01-11 2022-10-26 Samsung Bioepis Co., Ltd. PHARMACEUTICAL COMPOSITION WITH ANTIBODIES, DEVICE CONTAINING THIS AND USE THEREOF
EP3927729A4 (en) * 2019-02-18 2023-10-11 Eli Lilly and Company THERAPEUTIC ANTIBODY FORMULATION
JP2022546400A (ja) * 2019-08-30 2022-11-04 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー 高濃度の薬理学的に活性な抗体の新規製剤
KR20220152540A (ko) * 2020-03-13 2022-11-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물
WO2021234584A1 (en) * 2020-05-21 2021-11-25 Shilpa Biologicals Private Limited Pharmaceutical compositions comprising adalimumab
CN116963775A (zh) * 2021-03-03 2023-10-27 爱乐科斯公司 抗siglec-8抗体制剂
WO2023037384A1 (en) * 2021-09-07 2023-03-16 Dr. Reddy's Laboratories Limited Formulations of immune check point inhibitors or like
AU2022348349A1 (en) * 2021-09-16 2024-05-02 Aprogen Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFα ANTIBODY
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂
WO2023183898A1 (en) * 2022-03-24 2023-09-28 Arch Oncology, Inc. Formulations for anti-cd47 antibodies

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DK0774963T3 (da) 1994-08-08 2001-01-29 Debiopharm Sa Farmaceutisk stabilt oxaliplatin-præparat
CA2195557C (en) 1994-08-12 2006-10-17 Shui-On Leung Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6171576B1 (en) 1995-11-03 2001-01-09 Organix Inc. Dopamine transporter imaging agent
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0938334A4 (en) 1996-07-26 2004-12-15 Smithkline Beecham Corp IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3919235B2 (ja) * 1997-06-13 2007-05-23 ジェネンテク，インコーポレイテッド 抗体製剤
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6171686B1 (en) 1997-10-03 2001-01-09 Marine Environmental Solutions, L.L.C. Synthetic aquatic structure
DE59804785D1 (de) 1997-11-22 2002-08-22 Roche Diagnostics Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6281336B1 (en) 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
KR20140094647A (ko) 1999-03-25 2014-07-30 아비에 도이치란트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
ES2308978T3 (es) 1999-04-09 2008-12-16 Ortho-Mcneil Pharmaceutical, Inc. Composicion farmaceutica de eritropoyetina.
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
US20030124119A1 (en) * 1999-12-28 2003-07-03 Tadao Yamazaki Stable antibody compositions and injection preparations
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
ES2618832T3 (es) 2002-02-27 2017-06-22 Immunex Corporation Composición TNFR-FC estabilizada que comprende arginina
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
CA2491478A1 (en) 2002-07-09 2004-01-15 Sandoz Ag Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7674885B2 (en) 2002-11-01 2010-03-09 Bayer Healthcare Llc Process for concentration of macromolecules
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
JPWO2005063291A1 (ja) * 2003-12-25 2007-07-19 麒麟麦酒株式会社 抗体を含有する安定な水性医薬製剤
WO2006022599A1 (en) 2004-08-27 2006-03-02 Marian Metke Production method for exfoliated graphite, equipment for its production, exfoliated graphite and means of its use
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
KR101378194B1 (ko) 2005-12-20 2014-03-27 브리스톨-마이어스 스큅 컴퍼니 안정한 단백질 제제
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
AU2008232902B2 (en) * 2007-03-30 2013-10-03 Medlmmune, Llc Antibody formulation
AU2008248780B2 (en) 2007-05-02 2013-01-31 F. Hoffmann-La Roche Ag Method for stabilizing a protein
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US20090151807A1 (en) 2007-08-07 2009-06-18 Davis Chanda Janese Container Insert for Zero Headspace
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009073805A2 (en) 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP6078217B2 (ja) * 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 粉末化されたタンパク質組成物及びその作製方法
SG10201702922VA (en) * 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
US20100172862A1 (en) 2008-11-28 2010-07-08 Abbott Laboratories Stable antibody compositions and methods of stabilizing same
JP2012511531A (ja) 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
MY165614A (en) 2009-11-20 2018-04-18 Biocon Ltd Formulations of antibody
MX2012007676A (es) * 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
JP5937523B2 (ja) * 2010-03-01 2016-06-22 サイトダイン インコーポレイテッドＣｙｔｏＤｙｎ， Ｉｎｃ． 濃縮されたタンパク質製剤およびその使用
RU2600847C2 (ru) 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
CH703405B1 (de) 2010-07-05 2014-05-15 Melexis Tessenderlo Nv Magnetischer Winkelsensor.
AU2011291462A1 (en) * 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
AU2011301803A1 (en) * 2010-09-17 2013-03-21 Baxalta GmbH Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH
ME02506B (me) 2010-11-11 2017-02-20 Abbvie Biotechnology Ltd VISOKA KONCETRACIJA TEČNIH FORMULACIJA ANTI TNF alfa ANTITIJELA
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
JP5996631B2 (ja) 2011-04-20 2016-09-21 サンド・アクチエンゲゼルシヤフト ＴＮＦＲ：Ｆｃ融合タンパク質の安定した医薬液剤
KR20140023358A (ko) 2011-05-19 2014-02-26 노파르티스 아게 선양 낭성 암종의 치료에 사용하기 위한 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
DK2726090T3 (da) 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP2771033A4 (en) 2011-10-28 2016-02-17 Integritybio Inc PROTEIN FORMULATIONS CONTAINING AMINO ACIDS
WO2013096835A1 (en) 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
AU2013255413C1 (en) 2012-03-07 2016-03-24 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150102042A1 (en) 2012-07-10 2015-04-16 Gary Matsch Air Purging Lid
TWI698253B (zh) 2012-09-07 2020-07-11 美商柯赫勒斯生物科學有限公司 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
CN102988984B (zh) 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
EP2996621B1 (en) 2013-05-13 2018-06-20 EndoChoice, Inc. An endoscope tip position visual indicator and heat management system
US9681695B2 (en) 2013-07-31 2017-06-20 Sport Maska Inc. Helmet with chin cup

Also Published As

Publication number Publication date
IL277652B2 (en) 2023-04-01
DK2892550T3 (da) 2020-03-30
US20190070294A1 (en) 2019-03-07
US20180311350A1 (en) 2018-11-01
EA029215B1 (ru) 2018-02-28
US9757454B2 (en) 2017-09-12
US10207000B2 (en) 2019-02-19
US20180028654A1 (en) 2018-02-01
AU2018208699A1 (en) 2018-08-16
EP2892550A4 (en) 2016-04-13
SG10201705668XA (en) 2017-08-30
US9731009B2 (en) 2017-08-15
JP2019069993A (ja) 2019-05-09
US10716853B2 (en) 2020-07-21
EP2892550B1 (en) 2019-12-18
US20180028656A1 (en) 2018-02-01
CY1123407T1 (el) 2021-12-31
US9782479B2 (en) 2017-10-10
US20180028653A1 (en) 2018-02-01
PT2892550T (pt) 2020-03-27
US20180055930A1 (en) 2018-03-01
LT2892550T (lt) 2020-04-10
US10772959B2 (en) 2020-09-15
MX2015003007A (es) 2015-06-05
US20180311352A1 (en) 2018-11-01
US10155039B2 (en) 2018-12-18
US10159732B2 (en) 2018-12-25
US20160303233A1 (en) 2016-10-20
TWI698253B (zh) 2020-07-11
JP2021020930A (ja) 2021-02-18
US20190070293A1 (en) 2019-03-07
US9382317B2 (en) 2016-07-05
EP3701968A1 (en) 2020-09-02
IL237583A0 (en) 2015-04-30
EA201791717A1 (ru) 2018-03-30
CA2884182C (en) 2022-06-14
US20160256545A1 (en) 2016-09-08
US10286071B2 (en) 2019-05-14
IL237583B (en) 2020-10-29
US20170072054A1 (en) 2017-03-16
WO2014039903A2 (en) 2014-03-13
US20160303235A1 (en) 2016-10-20
WO2014039903A3 (en) 2014-06-26
AU2020202912A1 (en) 2020-05-21
US20180311351A1 (en) 2018-11-01
US20170312361A1 (en) 2017-11-02
US9724415B2 (en) 2017-08-08
US9682145B2 (en) 2017-06-20
US20180043019A1 (en) 2018-02-15
CL2015000574A1 (es) 2015-10-23
TW202042841A (zh) 2020-12-01
US20150191539A1 (en) 2015-07-09
IL277652B (en) 2022-09-01
BR112015004984A2 (pt) 2017-07-04
US9340612B2 (en) 2016-05-17
US10772960B2 (en) 2020-09-15
US10716854B2 (en) 2020-07-21
US20190070292A1 (en) 2019-03-07
US9782480B2 (en) 2017-10-10
US20190060455A1 (en) 2019-02-28
HK1210601A1 (en) 2016-04-29
US20160304599A1 (en) 2016-10-20
US20140186361A1 (en) 2014-07-03
JP6783845B2 (ja) 2020-11-11
US9731008B2 (en) 2017-08-15
US10780163B2 (en) 2020-09-22
US20150190513A1 (en) 2015-07-09
US20160039926A1 (en) 2016-02-11
TW201424749A (zh) 2014-07-01
US9707293B2 (en) 2017-07-18
US10716852B2 (en) 2020-07-21
RS60226B1 (sr) 2020-06-30
US10786566B2 (en) 2020-09-29
US10799585B2 (en) 2020-10-13
CA3153799A1 (en) 2014-03-13
EA201590518A1 (ru) 2016-05-31
US20180028655A1 (en) 2018-02-01
HRP20200434T1 (hr) 2020-07-24
US20160256547A1 (en) 2016-09-08
US20180140701A1 (en) 2018-05-24
US9789185B2 (en) 2017-10-17
SI2892550T1 (sl) 2020-11-30
US20180043018A1 (en) 2018-02-15
US20150190512A1 (en) 2015-07-09
US20180028657A1 (en) 2018-02-01
US9724414B2 (en) 2017-08-08
JP2015527402A (ja) 2015-09-17
KR20220025196A (ko) 2022-03-03
US9861695B2 (en) 2018-01-09
US9808525B2 (en) 2017-11-07
DOP2015000051A (es) 2015-05-31
KR20150047140A (ko) 2015-05-04
US9737600B2 (en) 2017-08-22
US20160304600A1 (en) 2016-10-20
US20160263226A1 (en) 2016-09-15
US10722579B2 (en) 2020-07-28
JP6463268B2 (ja) 2019-01-30
US20180311349A1 (en) 2018-11-01
US10195275B2 (en) 2019-02-05
CA2884182A1 (en) 2014-03-13
KR102362829B1 (ko) 2022-02-15
CN104768576A (zh) 2015-07-08
AU2013312300A1 (en) 2015-04-16
US20160256546A1 (en) 2016-09-08
KR20210040470A (ko) 2021-04-13
EP2892550A2 (en) 2015-07-15
US20150182626A1 (en) 2015-07-02
HUE049282T2 (hu) 2020-09-28
US10286072B2 (en) 2019-05-14
PE20150964A1 (es) 2015-07-25
US20150191538A1 (en) 2015-07-09
US20180055929A1 (en) 2018-03-01
ES2784861T3 (es) 2020-10-01
US10159733B2 (en) 2018-12-25
US20160303234A1 (en) 2016-10-20
PE20191815A1 (es) 2019-12-27
PL2892550T3 (pl) 2020-07-27
US9340611B2 (en) 2016-05-17
US20160031982A1 (en) 2016-02-04
KR102238677B1 (ko) 2021-04-12
IL277652A (en) 2020-11-30
US20160304601A1 (en) 2016-10-20
UY35351A (es) 2014-08-29
US9346880B2 (en) 2016-05-24
US20180021433A1 (en) 2018-01-25
US10688183B2 (en) 2020-06-23
AR092470A1 (es) 2015-04-22
SG11201501715QA (en) 2015-05-28
US9770507B2 (en) 2017-09-26

Similar Documents

Publication Publication Date Title
ECSP15013227A (es) Formulaciones acuosas estables de adalimumab
PH12019500176A1 (en) Heterocyclic compounds and ther uses
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017003316A1 (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen.
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
AR088379A1 (es) Formulaciones de etanercept estabilizadas con iones metalicos
UY34698A (es) Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP14008757A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
PH12016500720A1 (en) Stable formulation of insulin glulisine
BR112015025814A2 (pt) composição farmacêutica para uso inalatório, processo para a preparação de uma composição farmacêutica, composição sólida para uso como um diluente de pós para inalação e kit para a administração de um fármaco como pó para inalação
WO2014153495A3 (en) Novel stat3 inhibitors
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
CO2017007316A2 (es) Formulación farmacéutica
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
CO2019000083A2 (es) Composiciones farmacéuticas
EA201400444A1 (ru) Производные 2-оксопиперидинила
BR112013027391A2 (pt) formulação farmacêutica, frasco e kit